US2364579A - Hog cholera vaccine - Google Patents
Hog cholera vaccine Download PDFInfo
- Publication number
- US2364579A US2364579A US418839A US41883941A US2364579A US 2364579 A US2364579 A US 2364579A US 418839 A US418839 A US 418839A US 41883941 A US41883941 A US 41883941A US 2364579 A US2364579 A US 2364579A
- Authority
- US
- United States
- Prior art keywords
- virus
- vaccine
- hog cholera
- hog
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005004 cholera vaccine Drugs 0.000 title description 5
- 229960005486 vaccine Drugs 0.000 description 29
- 241000700605 Viruses Species 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 12
- 206010008631 Cholera Diseases 0.000 description 10
- 241000282887 Suidae Species 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 7
- 241000710777 Classical swine fever virus Species 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 4
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- This invention relates to the production of a hog cholera virus vaccine and is more particu-' larly concerned with such a vaccine associated with a finely divided adsorbing agent.
- An illustrative vaccine is made by the followin A highly infectious spleen of a hog fully diseased with hog cholera is taken with suitable steril precautions. finely ground in a colloid mill or by some other suitable device and made to a 5% tissue suspension with sterile distilled water. After standing for several hours in a refrigerator, this spleen suspension is cleared of gross particles by low-speed centrifugation or in some other suitable fashion. Enough freshly drawn, highly infectious virus blood is then added to make the suspension 10% with respect to this blood. To.
- the fluid thus obtained a 10% potash alum solution is slowly added with constant shaking until the pH of the final mixture has reached a value of 5.2, as determined by measurement with a glass electrode or other pH measuring device of suiiicient accuracy.
- a brown precipitate is formed in the liquid shortly after addition of the potash alum solution starts and continues as long as this addition proceeds.
- the suspension is allowed to stand for at least a day in the refrigerator beforefurther use. A better vaccine will result if the mixture is shaken continuously duringthe first 24 hours.
- v During the manufacture of the vaccine enough phenol is added to make it 0.5% with respect to this chemical. After one or more clays ageing, and after appropriate tests to insure bacterial sterility, the vaccine is ready to use.
- This adsorbed-virus vaccine could be made in a Other virus-containing number of other ways. organs of the hog, such as the liver, lymph nodes, blood, lungs, etc., could be used. Grinding could be carried out in different ways to provid a finer or a coarser suspension. Different proportions of tissue extract and of virus blood could be employed. Another adsorbent than hydrous aluminum oxide could be added or formed in the solution. The suspension could be made up with physiological salt solution or with buffered salt solution in place of distilled water.
- the hydrous oxide precipitate could be made using aluminum salts other than potash alum.
- alum solution was added to the amount-of approximately 0.2% in th virus suspension; satisfactory vaccine could be made with other amounts of alum especially if appropriate amounts of acid or alkali were added to give a final pH of 5.2.
- other adsorbents than hydrousaluminum oxide could be formed in the virus solution or introduced into it for the production of satisfactory vaccine.
- Suitabl adsorbents include calcium phosphate, silica gel, adsorbent'carbon, kieselguhr and similar materials which have no deleteriou effect when injected withthe vaccine.
- the ratio of adsorbed virus to free virus is not especially critical It is a very important advantage of a vaccine compounded as outlined above that it is much more stable on storage than is the usual virus blood vaccine and that in consequence it has a much lengthened useful life.
- McBryde and his coworkers of the United States Bureau of Animal Industry demonstrated that the optimum stability of the virus of hog cholera occurred not at the neutral pH of the blood but in an acid medium of pH 5.2. In reporting this work, these authors pointed out the advantages that would accrue from keeping and using virus at this acid pH, but they concluded that it was not practical since their blood vaccine gelled and solidified on being acidified.
- a typical use of adsorbed-virus vaccine for the active immunization of hogs is the following: 60 pound, susceptible hogs are injected subcutaneously with 2 cc. of my partially adsorbed-virus vaccine. At the same time 14 cc. of hyperimmune hog serum is injected subcutaneously into the hog at another point. During the next two weeks vaccinated pigs may be expected to acquire an active immunity to hog cholera without exhibiting any fever or other clinical manifestations of the disease. This immunity may be demonstrated three weeks or more after injection by the subcutaneous injection of 1 cc. of highly virulent hog cholera. virus.
- a hog cholera vaccine comprising hog cholera virus associated with hydrous aluminum oxide and an aqueous fluid in such an amount that part of the hog cholera virus is adsorbed onto the aluminum hydroxide, the rest being free in the liquid.
- a hog cholera vaccine comprising hog cholera virus associated with hydrous aluminum oxide and an aqueous fluid in such an amount that part of the virus is adsorbed onto the aluminum hydroxide, the rest being free in the fluid and the entire mixture being at a pH of approximately 5.2.
- the resulting suspension contains part of the virus adsorbed to the precipitated aluminum hydroxide and the rest of the virus is free in the aqueous fluid.
- a process of preparing a hog cholera vaccine which comprises forming an aqueous suspension of infectious hog cholera virus, adding to the suspension an aqueous solution of potash alum until the mixture has a pH of about 5.2 whereby colloidal aluminum hydroxide is precipitated, the amount of aluminum hydroxide being such as to adsorb most but not all of the-virus.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
. procedure.
Armed Dec. 5, 1944 Boo CHOLERA VACCINE Ralph W. G. Wyckofl, Suflern, N. Y., assignor to Lederle Laboratories, Inc., New York, N. Y., a corporation of Delaware No Drawing. Application November 12, 1941, Serial No. 418,839
. 4 Claims. (Cl. 167-80) This invention relates to the production of a hog cholera virus vaccine and is more particu-' larly concerned with such a vaccine associated with a finely divided adsorbing agent.
This application is in part a continuation of my prior application Serial No. 332,503 filed April 30, 1940.
In the standard mode of vaccination of hogs against hog cholera, hyperimmune serum and virus are administered at the same time, there thus being produced a low-grade and controlled infection which gives rise to a powerful and lastin immunity. For successful vaccination by this methodgappropriate amounts of serum and virus must be administered; if too much virus in relation to serum is given; disease may result; if too little, adequate protection will not develop. In practical use it is difficult to be assured of a proper balance between these two agents because the virus vaccine now employed progressively loses potency. on standing. At present one seeks to circumvent this difficulty by giving the virus vaccine a short dating, but this procedure is at best only partially satisfactory and it is at the same time wasteful and costly.
It is one of the objects of the present invention to produce a cheaper, more stable and more effective virus vaccine for the active immunization of hogs against hog cholera. It is a further object to put the vaccine in such a form (1) that a less critical balance against serum will result, (2) that the minimal amount of serum will be required to counterbalance the virus necessary for successful vaccination, and (3) that the highest possible degree of immunity will be established through vaccination by the gradual, and pro' longed liberation of virus Within the body of the hog being immunized.
These and other objects are obtained by a vaccine containing aluminum hydroxide or other suitable finely divided adsorbing agent, preferably colloidal, in such an amount that part, but
. not all, of the virus from infected tissue or blood is adsorbed thereon. When such a partiallyadsorbed virus vaccin is injected into a susceptible hog, the free virus it contains is immediately available to initiate the immunizing process while the gradual liberation of that part .of
the infectious principle which is adsorbed insures a continued low-grade infection resulting in a high degree of resultant immunity.
An illustrative vaccine is made by the followin A highly infectious spleen of a hog fully diseased with hog cholera is taken with suitable steril precautions. finely ground in a colloid mill or by some other suitable device and made to a 5% tissue suspension with sterile distilled water. After standing for several hours in a refrigerator, this spleen suspension is cleared of gross particles by low-speed centrifugation or in some other suitable fashion. Enough freshly drawn, highly infectious virus blood is then added to make the suspension 10% with respect to this blood. To. the fluid thus obtained a 10% potash alum solution is slowly added with constant shaking until the pH of the final mixture has reached a value of 5.2, as determined by measurement with a glass electrode or other pH measuring device of suiiicient accuracy.- A brown precipitate ,begins to form in the liquid shortly after addition of the potash alum solution starts and continues as long as this addition proceeds. After the proper pH has been reached, the suspension is allowed to stand for at least a day in the refrigerator beforefurther use. A better vaccine will result if the mixture is shaken continuously duringthe first 24 hours. v During the manufacture of the vaccine enough phenol is added to make it 0.5% with respect to this chemical. After one or more clays ageing, and after appropriate tests to insure bacterial sterility, the vaccine is ready to use.
\ This adsorbed-virus vaccine could be made in a Other virus-containing number of other ways. organs of the hog, such as the liver, lymph nodes, blood, lungs, etc., could be used. Grinding could be carried out in different ways to provid a finer or a coarser suspension. Different proportions of tissue extract and of virus blood could be employed. Another adsorbent than hydrous aluminum oxide could be added or formed in the solution. The suspension could be made up with physiological salt solution or with buffered salt solution in place of distilled water.
The hydrous oxide precipitate could be made using aluminum salts other than potash alum.
In the typical example cited above, alum solutionwas added to the amount-of approximately 0.2% in th virus suspension; satisfactory vaccine could be made with other amounts of alum especially if appropriate amounts of acid or alkali were added to give a final pH of 5.2. As stated above, other adsorbents than hydrousaluminum oxide could be formed in the virus solution or introduced into it for the production of satisfactory vaccine. Suitabl adsorbents include calcium phosphate, silica gel, adsorbent'carbon, kieselguhr and similar materials which have no deleteriou effect when injected withthe vaccine. The ratio of adsorbed virus to free virus is not especially critical It is a very important advantage of a vaccine compounded as outlined above that it is much more stable on storage than is the usual virus blood vaccine and that in consequence it has a much lengthened useful life. In a work published several years ago, McBryde and his coworkers of the United States Bureau of Animal Industry demonstrated that the optimum stability of the virus of hog cholera occurred not at the neutral pH of the blood but in an acid medium of pH 5.2. In reporting this work, these authors pointed out the advantages that would accrue from keeping and using virus at this acid pH, but they concluded that it was not practical since their blood vaccine gelled and solidified on being acidified. The preparation of my partially adsorbed-virus vaccine at a 'pH of about 5.2 for the first time makes it possible to take advantage of the greatly enhanced stability of hog cholera virus at its point of maximum stability, since at this pH adsorption of the virus occurs under optimal conditions.
It is a further advantage of my partially adsorbed-virus vaccine that less than the usually recommended amount of serum need be used with it for the entirely safe and highly effective immunization of pigs. Safe vaccination can be obtainedwith a minimal dose of serum using my vaccine since the virus which is immediately liberated and must be counteracted by the added serum constitutes only a fraction of the total that is present in the injected vaccine.
A typical use of adsorbed-virus vaccine for the active immunization of hogs is the following: 60 pound, susceptible hogs are injected subcutaneously with 2 cc. of my partially adsorbed-virus vaccine. At the same time 14 cc. of hyperimmune hog serum is injected subcutaneously into the hog at another point. During the next two weeks vaccinated pigs may be expected to acquire an active immunity to hog cholera without exhibiting any fever or other clinical manifestations of the disease. This immunity may be demonstrated three weeks or more after injection by the subcutaneous injection of 1 cc. of highly virulent hog cholera. virus. It will be found that the immunity is sufficiently great so that no symptoms of hog cholera result from the administration of this test dose of virus. Two vaccinated control hogs receiving such a test dose ofvirus will develop fever and other symptoms of hog cholera in from 5 to 8 days after injection and will usually succumb to the disease within two weeks.
At the present time more than 1000 hogs have been immunized successfully with my vaccine using the scheme outlined above. In vaccinating these animals there have been no untoward reactions and no cases. of hog cholera have developed in a vaccinated animal either during the vaccination or at the subsequent time. Some of .cination with partially adsorbed-virus vaccine.
Successful vaccination would, however, result from the administration of a larger amount of serum and smaller amounts also could be used.
If very small volumes of serum are employed,
many pigs will be successfully vaccinated but a certain percentage may exhibit more or less severe symptoms of an active hog cholera infection. On
account of the gradual liberation of the infectious principle from my adsorbed-virus vaccine, a wider latitude is permissible in the amount of serum to be administered for safe and solid in!- munization.
For the purposes of sterilizing the vaccine, I may use other proportions of phenol than that specifically described. Likewise, any other antiseptic may be employed for all, or a part, of the phenol.
It will be obvious that other changes and variations may be made in preparing my vaccine and the invention is not restricted to the specific details described except as set forth in the claims.
I claim:
1. A hog cholera vaccine comprising hog cholera virus associated with hydrous aluminum oxide and an aqueous fluid in such an amount that part of the hog cholera virus is adsorbed onto the aluminum hydroxide, the rest being free in the liquid.
2. A hog cholera vaccine comprising hog cholera virus associated with hydrous aluminum oxide and an aqueous fluid in such an amount that part of the virus is adsorbed onto the aluminum hydroxide, the rest being free in the fluid and the entire mixture being at a pH of approximately 5.2.
ide in an amount such that the resulting suspension contains part of the virus adsorbed to the precipitated aluminum hydroxide and the rest of the virus is free in the aqueous fluid.
4. A process of preparing a hog cholera vaccine which comprises forming an aqueous suspension of infectious hog cholera virus, adding to the suspension an aqueous solution of potash alum until the mixture has a pH of about 5.2 whereby colloidal aluminum hydroxide is precipitated, the amount of aluminum hydroxide being such as to adsorb most but not all of the-virus.
RALPH W. G. WYCKOFF.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US418839A US2364579A (en) | 1941-11-12 | 1941-11-12 | Hog cholera vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US418839A US2364579A (en) | 1941-11-12 | 1941-11-12 | Hog cholera vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US2364579A true US2364579A (en) | 1944-12-05 |
Family
ID=23659750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US418839A Expired - Lifetime US2364579A (en) | 1941-11-12 | 1941-11-12 | Hog cholera vaccine |
Country Status (1)
Country | Link |
---|---|
US (1) | US2364579A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3925545A (en) * | 1972-04-06 | 1975-12-09 | Pasteur Institut | Process for preparing adsorbed vaccines |
US4551431A (en) * | 1983-04-21 | 1985-11-05 | Phillips Petroleum Company | The use of gallium and indium salts for the immobilization of proteins |
-
1941
- 1941-11-12 US US418839A patent/US2364579A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3925545A (en) * | 1972-04-06 | 1975-12-09 | Pasteur Institut | Process for preparing adsorbed vaccines |
US4551431A (en) * | 1983-04-21 | 1985-11-05 | Phillips Petroleum Company | The use of gallium and indium salts for the immobilization of proteins |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0007891B1 (en) | process for producing il-1ra in a syringe for use as a medicine | |
US3456053A (en) | Inactivated hog cholera virus vaccine | |
US2491537A (en) | Liquid injectable oil-pectin-drug therapeutic compositions | |
US3269912A (en) | Aluminum oxide depot vaccines | |
JPH0639386B2 (en) | Production method of live adjuvant vaccine | |
Bailey et al. | Modified oesophagoscope for injecting oesophageal varices. | |
US3720761A (en) | Injectable radio-pharmaceutical scanning agent and preparation | |
KR0162074B1 (en) | Solutions containing antigen and zinc hydroxide or iron hydroxide as an adjuvant and processes for preparing such solutions | |
US2411897A (en) | Pharmaceutical solution | |
US2364579A (en) | Hog cholera vaccine | |
Necheles | Effects of glucagon on external secretion of the pancreas | |
US2518510A (en) | Stable injectable oil-pectin therapeutic compositions | |
US3629425A (en) | Stabilized 2-pam solutions | |
KR100195571B1 (en) | Antigen solution treated with zinc hydroxide/calcium hydroxide gel. lecithin and polyalphaolefin and preparation thereof | |
US3639577A (en) | Injectable adjuvant,method of preparing same and compositions including such adjuvant | |
Rose et al. | Studies on the release of histamine from the blood cells of the rabbit by the addition of horse serum or egg albumin in vitro | |
Rhoads | Immunization with mixtures of poliomyelitis virus and aluminum hydroxide | |
JPS62249928A (en) | Medicine for radiation trouble | |
US4600582A (en) | Therapeutic treatment | |
US2487975A (en) | Therapeutic preparations for intramuscular or subcutaneous injection and methods of making the same | |
US2793156A (en) | Repository penicillin products | |
US2415719A (en) | Gelatin vehicle | |
US3097140A (en) | Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride | |
Gourzis et al. | Alterations in Cardiovascular Responses of the Dog Following Rauwiloid. An Alkaloidal Extract of Rauwolfia serpentina | |
GB2030043A (en) | Injectable composition for the treatment of helminthiasis and clostridial diseases in animals |